Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 11, Issue 8, 2005, Pages 707-712

  Solem, Craig A ^a   Loftus Jr , Edward V ^a   Tremaine, William J ^a   Harmsen, William S ^b   Zinsmeister, Alan R ^b   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

C reactive protein; Crohn's disease; Erythrocyte sedimentation rate; Inflammatory bowel disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; COLON RADIOGRAPHY; COLONOSCOPY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HIGH RISK PATIENT; HISTOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; CONFIDENCE INTERVALS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 24644474678     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000173271.18319.53     Document Type: Article

References (19)

1. Bitton A, Peppercorn M, Antonioli D, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
2. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10:401-405.
3. Pagan E, Dyck R, Maton P, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351-359.
4. Linskens R, van Bodegraven A, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001;46:644-648.
5. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol. 1995;30:356-360.
6. Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology. 1997;44:90-107.
7. Nielsen O, Vainer B, Madsen S, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
8. Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol. 1988;10:41-45.
9. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.
10. Mazlam M, Hodgson H. Interrelations between interleukin-6, interleukin-1beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut. 1994;35:77-83.
11. Schunk K, Kern A, Oberholzer K, et al. Hydro-MRI in Crohn's disease: appraisal of disease activity. Invest Radiol. 2000;35:431-437.
12. Gomes P, du Boulay C, Smith C, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95.
13. Rutgeerts P, Colombel J, Enns R, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Gut. 2003;52:A239.
14. Sandborn W, Feagan B, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493.
15. Schreiber S, Rutgeerts P, Fedorak R, et al. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease. [abstract] Gastroenterology. 2003; 124(suppl 1):A61.
16. Hanauer S, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
17. Kornbluth A, Sachar D. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
18. Shah S, Newby L. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 2003;11:169-179.
19. Solem C, Loftus E Jr, Fletcher J, et al. Small Bowel (SB) Imaging in Crohn's Disease (CD): A Prospective, Blinded, 4-Way Comparison Trial [Abstract] Gastroenterology. 2005;128:A74.